TOT BIOPHARM International Co Ltd
HKEX:1875
Intrinsic Value
TOT BIOPHARM International Co. Ltd. clinical stage biopharmaceutical company, which engages in developing and commercializing oncology drugs and therapies. [ Read More ]
The intrinsic value of one TOT BIOPHARM International Co Ltd stock under the Base Case scenario is 2.63 HKD. Compared to the current market price of 2 HKD, TOT BIOPHARM International Co Ltd is Undervalued by 24%.
Valuation Backtest
TOT BIOPHARM International Co Ltd
Run backtest to discover the historical profit from buying and selling TOT BIOPHARM International Co Ltd stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
TOT BIOPHARM International Co Ltd
| Current Assets | 693.2m |
| Cash & Short-Term Investments | 351.6m |
| Receivables | 143.1m |
| Other Current Assets | 198.5m |
| Non-Current Assets | 732.9m |
| Long-Term Investments | 2.8m |
| PP&E | 711.9m |
| Intangibles | 8.8m |
| Other Non-Current Assets | 9.4m |
| Current Liabilities | 382.5m |
| Accounts Payable | 322.9m |
| Other Current Liabilities | 59.6m |
| Non-Current Liabilities | 356.9m |
| Long-Term Debt | 302.9m |
| Other Non-Current Liabilities | 54.1m |
Earnings Waterfall
TOT BIOPHARM International Co Ltd
|
Revenue
|
780.6m
CNY
|
|
Cost of Revenue
|
-206.6m
CNY
|
|
Gross Profit
|
574m
CNY
|
|
Operating Expenses
|
-595.6m
CNY
|
|
Operating Income
|
-21.6m
CNY
|
|
Other Expenses
|
-16.2m
CNY
|
|
Net Income
|
-37.8m
CNY
|
Free Cash Flow Analysis
TOT BIOPHARM International Co Ltd
Profitability Score
Profitability Due Diligence
TOT BIOPHARM International Co Ltd's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
Score
TOT BIOPHARM International Co Ltd's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
TOT BIOPHARM International Co Ltd's solvency score is 38/100. The higher the solvency score, the more solvent the company is.
Score
TOT BIOPHARM International Co Ltd's solvency score is 38/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
TOT BIOPHARM International Co Ltd
According to Wall Street analysts, the average 1-year price target for TOT BIOPHARM International Co Ltd is 3.88 HKD with a low forecast of 3.84 HKD and a high forecast of 3.99 HKD.
Shareholder Return
Price
TOT BIOPHARM International Co Ltd
| Average Annual Return | -21.15% |
| Standard Deviation of Annual Returns | 21.53% |
| Max Drawdown | -76% |
| Market Capitalization | 1.5B HKD |
| Shares Outstanding | 772 787 890 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
TOT BIOPHARM International Co. Ltd. clinical stage biopharmaceutical company, which engages in developing and commercializing oncology drugs and therapies. The company is headquartered in Suzhou, Jiangsu. The company went IPO on 2019-11-08. The firm has a portfolio of oncology drug candidates, which include monoclonal antibodies (mAbs), antibody drug conjugates (ADCs), oncolytic virus products and specialty oncology drugs such as liposome drugs.
Contact
IPO
Employees
Officers
The intrinsic value of one TOT BIOPHARM International Co Ltd stock under the Base Case scenario is 2.63 HKD.
Compared to the current market price of 2 HKD, TOT BIOPHARM International Co Ltd is Undervalued by 24%.
You don't have any saved screeners yet
